Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Cervical Neoplasms × defactinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Ovarian Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Neoplasms, Mesothelial 1 Mesothelioma 1 Low-Grade Serous Ovarian Cancer 1 Advanced Colorectal Cancer 1 Adenoma 1 Adenocarcinoma of Lung 1

Interventions

Cisplatin 56 Paclitaxel 25 Radiotherapy 24 Carboplatin 21 Bevacizumab 20 pembrolizumab 18 Brachytherapy 15 atezolizumab 9 Gemcitabine 9 camrelizumab 8 Topotecan 8 Nivolumab 8 Radiation 7 zimberelimab 6 tislelizumab 6 Docetaxel 6 Albumin-Bound Paclitaxel 6 toripalimab 5 nimotuzumab 5 lenvatinib 5 dostarlimab 5 Taxes 5 Papillomavirus Vaccines 5 Drug Therapy 5 Chemoradiotherapy 5 Cetuximab 5 durvalumab 4 Platinum 4 Magnetic Resonance Spectroscopy 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05512208 2025-10-22

DURAFAK

University of Oklahoma

Phase 2 Recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡